• search hit 61 of 221
Back to Result List

Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons

  • The high rate of restenosis associated with percutaneous coronary intervention (PCI) procedures can be reduced with the implantation of metallic stents into the stenotic vessels. The knowledge that neointimal formation can result in restenosis after stent implantation led to the development of drug-eluting stents (DES) which require long lasting antiplatelet therapy to avoid thrombotic complications. In the last years, the drug-eluting balloon (DEB) technology has emerged as an alternative option for the treatment of coronary and peripheral arteries. Clinical studies demonstrated the safety and effectiveness of DEB in various clinical scenarios and support the use of paclitaxel-eluting balloons for the treatment of in-stent restenosis, of small coronary arteries and bifurcations lesions. The protocols of DEB studies suggest that the dual antiplatelet therapy with aspirin and clopidogrel of four weeks after DEB is safe and effective.

Export metadata

Additional Services

Share in Twitter Search Google Scholar Statistics
Author:Klaus Bonaventura, Steffen Sonntag, Franz X. Kleber
ISSN:1774-024X (print)
Parent Title (English):EuroIntervention : official journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)
Publisher:Universitätsverlag Potsdam
Place of publication:Toulouse
Document Type:Article
Year of first Publication:2011
Year of Completion:2011
Release Date:2017/03/26
Tag:clopidogrel; coronary artery disease; drug-eluting balloon; drug-eluting stent
First Page:K106
Last Page:K111
Funder:B.Braun; Invatec; Biotronik
Organizational units:Humanwissenschaftliche Fakultät / Institut für Sportmedizin und Prävention
Peer Review:Referiert